



Prostate Cancer—from Molecular Mechanisms to Clinical Care

Collection Editors:

Dr. Alfonso Urbanucci

Department of Tumor Biology,
Institute for Cancer Research,
Oslo University Hospital, 0424
Oslo, Norway

Dr. Delila Gasi Tandefelt

Sahlgrenska Cancer Center,
Institute of clinical studies,
University of Gothenburg,
Gothenburg, Sweden

Message from the Collection Editors

Dear Colleagues,

Prostate cancer is the second leading cause of cancer-related death in men worldwide.

The treatment options for men with advanced form of the disease have been focused on targeting the androgen receptor signaling axes for decades. Recent technical developments that allow better resolution have increased our understanding of the molecular mechanisms that are important for prostate cancer biology and disease evolution.

As new, possibly druggable, targets are discovered and novel treatment options enter clinical trials, the need to improve the link between molecular discoveries and clinical management also increases.

This Collection will focus on the current status and challenges in treating early and progressive prostate cancer, covering topics from basic research and technical developments to specific new and emerging targets, and the clinical management of prostate cancer patients.

Dr. Alfonso Urbanucci
Dr. Delila Gasi Tandefelt
Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)